India Sterile Injectables Market Size Analysis
The India Sterile Injectables Market is estimated to account for 8% of Asia Pacific share in 2018. The industry is set to create 2.5X higher revenue opportunity for industry players by the end of 2028.
The industry is characterized by the presence of numerous small and large scale players operating primarily in Southern and Western parts of India. India has large addressable market wherein companies compete primarily among price level strategy. High population base has resulted in creating attractive business destinations for industry players. As such, various companies are eyeing to capitalize the India sterile injectables market.
Access Global Sterile Injectables Market Report with special focus across 27+ countries at: https://bekryl.com/industry-trends/sterile-injectable-market-size-analysis
Contract manufacturing and mergers and acquisitions are key trends witnessed in India sterile injectables market. In 2017, Pfizer acquired Hospira in US$ 17 Billion deal. The move has helped Pfizer to expand its generic sterile injectables portfolio – leading to strengthening of its business presence. In the same year, Baxter International Inc. acquired Claris Injectables to boost the supply to Baxter customers and in turn register high return on investment (ROI). Another major company, Endo International entered in definitive agreement to acquire Somerset Therapeutics and its affiliated contract manufacturer in India for US$ 190 million in 2018. Several such developments are expected to be seen in next few years in India sterile market.
There is pool of opportunity in India sterile injectables market, however, low level of IT integration and regulatory manufacturing are major challenge towards overall growth. Well-developed distribution channel across value chain will help manufacturers to gain larger market share.
Insight#1: Large Molecules to dominate the India Sterile Injectables Market Size
Biologics based injectables are still in naïve position in the country and will take time to witness significant growth. As of 2018, large molecules accounted for 63% of country share. The share will however decline with patent expiry in small molecules product.
Insight#2: Oncology to dominate the India Sterile Injectables Market by Therapeutic Application
High prevalence rate of cancers will lead to increase in supply of sterile injectables. It will account for majority of the country share. Small molecules will gain higher momentum owing to demand for effective treatment modalities.
Insight#3: Hospitals to account for majority of the product sales
Leading companies including Claris has strong sales presence and primarily operates through direct sales channel to ensure long term marketing stability. Other major companies are also pushing through direct sales presence. By distribution type, Hospitals will account for majority of the India sterile Injectables Market Size.
India Sterile Injectables Market Size and Forecast: Competition Landscape
Some leading sterile injectables market players are AAIPharma Services Corp, Accumedix, Inc., Piramal Pharma Solutions, Jubilant Life Sciences, Lomapharm, Pfizer, Sun Pharma, and Baxter International Inc.
India Sterile Injectables Market Industry Segmentation
(Request Sample, to access complete research framework, TOC and Key Insights)
By Product Type:
- Small Molecules
- Large Molecules
By Therapeutic Application:
- Cardiovascular Diseases
- Central Nervous Systems
- Infectious Disorders
By Route of Administration:
- Other Route of Administration
By Drug Type:
- Monoclonal Antibodies (mAbs)
- Peptide Hormones
- Blood Factors
- Peptide Antibiotics
By Distribution Channel:
- Drug Stores
- Online e-Commerce*